- Treatment
Landscape- ABSSSI
Treatment
Burden- ABSSSI
Treatment
Challenges- About
KIMYRSA®- What is
KIMYRSA®?- Mechanisms
of Action- PK Profile
- In Vitro
Results by Pathogen- Clinical
Studies- Clinical Study Information
- SOLO Studies
- Real-World
Experience- Real-World Studies
- Real Patient Results
- Single-Dose
Administration- Resources
and Support
Many patient factors can affect the clinical outcomes of multiday treatments1
Specific patient factors can decrease compliance1,2-4
- Elderly patients may lack the necessary support from family members1
- Patients with a history of nonadherence may be less likely to complete treatments1
- Intravenous drug users are at an increased risk for ABSSSIs but struggle with OPAT due to multiple potential complications2,3
- Patients with busy schedules and work commitments may be unable to take time off for multiple treatments1,4
Single-dose treatment may be preferable for many patients1
- A prospective investigation of data collected from 2009 to 2012, which included 87 participants, found that 46% of patients with ABSSSIs did not adhere to prescribed multidose oral antibiotic regimens post discharge5
- Multiple studies have shown that an increased number of doses and long duration of treatment can decrease adherence2
According to a multicenter noninterventional survey of patients with ABSSSIs conducted from 2016 to 2017, patients would prefer a single-dose infusion therapy6
83.9%
of patients (n=78)
reported definite or probable interest in single-dose intravenous antibiotic therapy if it helped them avoid hospitalization
More patients preferred home care (40.4%) compared with treatment in a hospital (25.5%), SNF (4.3%), or ED (1.1%)
Help give patients back their days
ABSSSI, acute bacterial skin and skin structure infection; ED, emergency department; LOS, length of stay; OPAT, outpatient parenteral antimicrobial therapy; SNF, skilled nursing facility; SoC, standard of care.
References: 1. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-286. doi:10.2147/tcrm.s1458 2. Redell M, Moeck G, Lucasti C, et al. A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open Forum Infect Dis. 2018;5(6):ofy051. doi:10.1093/ofid/ofy051 3. Buehrle DJ, Shields RK, Shah N, Shoff C, Sheridan K. Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users. Open Forum Infect Dis. 2017;4(3):ofx102. doi:10.1093/ofid/ofx102 4. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49(6):897-903. doi:10.1093/jac/dkf046 5. Eells SJ, Nguyen M, Jung J, Macias-Gil R, May L, Miller LG. Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with staphylococcus aureus skin infections. Antimicrob Agents Chemother. 2016;60(5):2941-2948. doi:10.1128/AAC.02626-15 6. Almarzoky Abuhussain SS, Burak MA, Kohman KN, et al. Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. BMC Health Serv Res. 2018;18(1):932. doi:10.1186/s12913-018-3751-0
*INDICATION AND USAGE
- Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and methicillin-resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of oritavancin and other antibacterial drugs, oritavancin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
- KIMYRSA® and ORBACTIV® are not approved for combination use and have differences in dose strength, duration of infusion, and preparation instructions, including reconstitution and dilution instructions and compatible diluents. Please see the full Prescribing Information for each product.
IMPORTANT SAFETY INFORMATION
Contraindications
- Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after oritavancin administration because the activated partial thromboplastin time (aPTT) test results may remain falsely elevated for approximately 120 hours (5 days) after oritavancin administration.
- Oritavancin products are contraindicated in patients with known hypersensitivity to oritavancin.
Warnings and Precautions
- Coagulation test interference: Oritavancin has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours and ACT for up to 24 hours. Oritavancin has also been shown to elevate D-dimer concentrations up to 72 hours. For patients who require aPTT monitoring within 120 hours of oritavancin dosing, consider a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT.
- Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of oritavancin products. Discontinue infusion if signs of acute hypersensitivity occur. Closely monitor patients with known hypersensitivity to glycopeptides.
- Infusion related reactions: Infusion reactions characterized by chest pain, back pain, chills and tremor have been observed with the use of oritavancin products, including after the administration of more than one dose of oritavancin during a single course of therapy. Stopping or slowing the infusion may result in cessation of these reactions.
- Clostridioides difficile-associated diarrhea: Evaluate patients if diarrhea occurs.
- Concomitant warfarin use: Oritavancin has been shown to artificially prolong PT/INR for up to 12 hours. Patients should be monitored for bleeding if concomitantly receiving oritavancin products and warfarin.
- Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.
- Prescribing oritavancin products in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.
Adverse Reactions
- The most common adverse reactions (≥3%) in patients treated with oritavancin products were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea. The adverse reactions occurring in ≥2 patients receiving KIMYRSA® were hypersensitivity, pruritus, chills and pyrexia.
Please see Full Prescribing Information for ORBACTIV®.
Please see Full Prescribing Information for KIMYRSA®.
SEE MORE
*INDICATION AND USAGE
Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be
IMPORTANT SAFETY INFORMATION
ContraindicationsUse of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after oritavancin
- Real Patient Results
- SOLO Studies
- Mechanisms
- ABSSSI
- ABSSSI
This site is intended for US Healthcare Professionals only.
